Clinical Trial

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 22, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets in TD patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-11.
Status change: Not Yet Recruiting → Recruiting 2025-01-20
Trial Details
NCT Number NCT06731868
Lead Sponsor Luye Pharma Group Ltd.
Conditions Tardive Dyskinesia (TD)
Enrollment 120 participants
Start Date 2025-01-14
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-22